定义混合表型急性白血病中两个生物学和临床不同的组别
该研究纳入一组混合表型(MP)急性白血病患者,通过临床、遗传和转录组特征将伴混合表型的急性髓系白血病(AML-MP)与混合表型急性白血病(MPAL)定义为两个不同组别。AML-MP对AML或ALL诱导方案反应较差(风险比12.5,95%CI 2.72-57.8,P=.001),而MPAL对ALL导向治疗反应较好;AML-MP中RUNX1和TP53突变更常见。
要点
- AML-MP对诱导治疗反应较差(HR 12.5,95%CI 2.72-57.8,P=.001),MPAL对ALL导向治疗反应较好
- AML-MP中RUNX1突变23/52(44%)、TP53突变12/52(23.1%),MPAL中RUNX1突变8/35(23%;P=.01 vs AML-MP)
- 治疗后AML-MP向淋系免疫表型转换罕见(1/40[2.5%] vs MPAL 10/28[35.7%];P=.0003)
核心结论
- 数据支持将AML-MP列为与MPAL不同的诊断实体,并为伴混合表型急性白血病的发病机制和治疗提供新见解。
研究设计与样本
- 研究纳入一大组伴混合表型(MP)的急性白血病患者,通过临床、遗传和转录组特征进行比较分析。
主要发现
- AML-MP和MPAL患者均接受AML或急性淋巴细胞白血病(ALL)导向的诱导方案治疗,AML-MP反应较差(风险比12.5;95%置信区间2.72-57.8;P=.001),而MPAL对ALL导向治疗反应较好。
- 遗传学上,AML-MP中RUNX1突变更常见(23/52[44%]),TP53突变12/52(23.1%);MPAL中RUNX1突变较少(8/35[23%];P=.01 vs AML-MP),TP53突变作为驱动基因在MPAL中几乎不存在。
- 转录组上,AML-MP富集干性特征,且髓系和淋系分化关键转录因子相对缺乏。
- 治疗后AML-MP向淋系免疫表型转换罕见,与MPAL相反(1/40[2.5%] vs 10/28[35.7%];P=.0003)。
- 研究提出一个基因组分类框架供未来研究使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A mixed phenotype (MP) is a characteristic of de novo MP acute leukemia (MPAL), but it can also be found in other leukemias. It poses substantial classification and management dilemmas. Herein, we report a large cohort of acute leukemia with MP and define acute myeloid leukemia with MP (AML-MP) and MPAL as 2 distinct groups by characterizing clinical, genetic, and transcriptomic features. Clinically, patients with AML-MP and MPAL were both treated with either AML- or acute lymphoblastic leukemia (ALL)-directed induction regimens. AML-MP has inferior responses (hazard ratio, 12.5; 95% confidence interval, 2.72-57.8; P = .001), whereas MPAL has better responses to ALL-directed treatment. Genetically, AML-MP harbors more frequent RUNX1 (23/52 [44%]) and TP53 (12/52 [23.1%]) mutations. In contrast, RUNX1 mutations are less frequent in MPAL (8/35 [23%]; P = .01 vs AML-MP) and TP53 mutations as a driver are virtually absent in MPAL. Transcriptionally, AML-MP shows enrichment for stemness signatures and a relative deficit of transcription factors critical for myeloid and lymphoid differentiation. Furthermore, AML-MP rarely switches to a lymphoid immunophenotype after treatment, in contrast to MPAL (1/40 [2.5%] vs 10/28 [35.7%]; P = .0003). Last, a genomic classification framework is proposed for future studies. Together, these data support the designation of AML-MP as a diagnosis distinct from MPAL and provide novel insights into the pathogenesis and therapies of acute leukemia with MP.
引用
- Galera P, Dilip D, Derkach A, et al. Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype. Blood. 2025. PMID: 39813682. doi:10.1182/blood.2024026273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。